ScientificScholar Knowledge is power

Journal of Neurosciences in Rural Practice



Review Article

Neutrophil-lymphocyte ratio as a predictor of outcome following traumatic brain injury: Systematic review and meta-analysis

Rakesh Kumar Mishra¹, Sagar Galwankar², Joel Gerber³, Anuj Jain⁴, Md. Yunus⁵, Rafael Cincu⁶, Luis Rafael Moscote-Salazar⁷, Gabriel Alexander Quiñones-Ossa⁸, Amit Agrawal⁹

¹Department of Neurosurgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India, Departments of ²Global Health and ³Emergency Medicine, University of South Florida, Tampa, Florida, United States, Departments of ⁴Anesthesia and ⁵Trauma and Emergency Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, ⁶Department of Neurosurgery, Valencia General Hospital, Valencia, Spain, ⁷Department of Neurosurgery, University of Cartagena, Bogota, Colombia, ⁸Department of Neurosurgery, Faculty of Medicine - Neurosurgery Resident, Universidad El Bosque, Bogotá, Colombia, ⁹Department of Neurosurgery, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.

ABSTRACT

Objectives: The neutrophil-to-lymphocyte ratio (NLR) is a simple and routinely performed hematological parameter; however, studies on NLR as a prognostic tool in traumatic brain injury (TBI) have yielded contradictory results.

Materials and Methods: This systematic review and meta-analysis was conducted according to the Preferred Reporting Items in the Systematic Review and Meta-Analysis guidelines 2020. Electronic databases of PubMed, Cochrane Library, Web of Science, and Scopus were searched. The population consisted of TBI patients in the absence of moderate and severe extracranial injury. Day 1 NLR was taken for the analysis. The outcomes evaluated were mortality and the Glasgow Outcome Scale (GOS). No restrictions were placed on the language, year and country of publication, and duration of follow-up. Animal studies were excluded from the study. Studies, where inadequate data were reported for the outcomes, were included in the qualitative synthesis but excluded from the quantitative synthesis. Study quality was evaluated using the Newcastle-Ottawa scale (NOS). The risk of bias was estimated using the Cochrane RoBANS risk of bias tool.

Results: We retrieved 7213 citations using the search strategy and 2097 citations were excluded based on the screening of the title and abstract. Full text was retrieved for 40 articles and subjected to the eligibility criteria, of which 28 were excluded from the study. Twelve studies were eligible for the synthesis of the systematic review while seven studies qualified for the meta-analysis. The median score of the articles was 8/9 as per NOS. The risk of selection bias was low in all the studies while the risk of detection bias was high in all except one study. Ten studies were conducted on adult patients, while two studies reported pediatric TBI. A meta-analysis for GOS showed that high NLR predicted unfavorable outcomes at ≥ 6 months with a mean difference of -5.18 (95% confidence interval: -10.04, -0.32); P = 0.04; heterogeneity (I²), being 98%. The effect estimates for NLR and mortality were a mean difference of -3.22 (95% confidence interval: -7.12, 0.68), P = 0.11, and an I² of 85%. Meta-analysis for Area under the curve (AUC) receiver operating characteristic of the included studies showed good predictive power of NLR in predicting outcomes following TBI with AUC 0.706 (95% CI: 0.582–0.829).

Conclusion: A higher admission NLR predicts an increased mortality risk and unfavorable outcomes following TBI. However, future research will likely address the existing gaps.

Keywords: Neutrophil-lymphocyte ratio, Traumatic brain injury, Outcome, Systematic review, Meta-analysis

INTRODUCTION

Traumatic brain injury (TBI) is a considerable noncommunicable disease and has emerged as a silent epidemic that affects economically and socially productive individuals. TBI is a complex and dynamic entity with its effects days after the injury. The primary injury primarily determines the outcome of the TBI patient at the time of impact, marked by brain damage, loss of function, and death. Apart from high mortality, there are significant complications in the individuals who survive, including poor functional outcomes, dementia, and infections.^[1-3] Jennett and Bond created the Glasgow Outcome Scale (GOS) as a 5-point objective measurement tool in 1975 to assess the TBI outcome.^[4] The goal of successful management in TBI is to prevent secondary injury. The key factors determining the outcome of TBI are age, gender, and immediate impact; however, these are non-modifiable.^[2] Immune changes in post-TBI are potentially modifiable factors and provide a therapeutic window to

*Corresponding author: Dr. Amit Agrawal, Department of Neurosurgery, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India. dramitagrawal@gmail.com

Received: 13 September 2022 Accepted: 21 September 2022 EPub Ahead of Print: 12 December 2022 Published: 16 December 2022 DOI: 10.25259/JNRP-2022-4-21

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. ©2022 Published by Scientific Scholar on behalf of Journal of Neurosciences in Rural Practice

Journal of Neurosciences in Rural Practice • Volume 13 • Issue 4 • October-December 2022 | 618

limit secondary brain injury and improve the outcome following TBI.^[1,5] Several prognostic indicators and tools such as IMPACT and CRASH are developed to guide the management and predict the outcome in TBI patients. These tools are used to predict short-term and long-term mortality and functional outcome. However, it is always not easy to obtain all the elements in the prognostic tools in different hospital settings. Accordingly, researchers attempted to identify simple biomarkers as hematological parameters to predict the outcomes.

Studies in trauma immunology and animal studies suggest the potential role of neutrophils in adverse sequelae following TBI.^[5] Neutrophils are critical components of the innate immune system which is the first defense against microbial infection. TBI is characterized by the increased immune response following injury and later by immune depression, leading to respiratory failure, multiorgan dysfunction, and nosocomial infection.^[6,7] Evidence from immunology studies suggests that neutrophils play a linking role between the innate immune response and chronic immune response.^[6] Several studies have attempted to explore the utility of simple hematological investigations in predicting the outcomes following TBI. Some studies have shown that neutrophillymphocyte ratio (NLR) has predictive power similar to GCS in predicting mortality and GOS outcome.[8-10] However, some studies suggest that the predictive performance of NLR is not superior to other predictive biomarkers.^[11,12] The present study aims to critically assess the available evidence and identify the knowledge gaps about NLR in predicting TBI outcomes.

MATERIALS AND METHODS

We have conducted the present study as per the guidelines of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement published in 2009 and updated in 2020.^[13]

Study design

This is a prognostic systematic review to evaluate the available evidence on NLR as a predictor of outcomes following TBI.

Eligibility criteria

Published studies were identified through electronic searches to answer the review question—"What is the prognostic value of the NLR as a predictor of outcome following a TBI?" Studies were screened for eligibility according to the PICO question framework.

- Population (P): Patients with TBI in whom NLR was measured at admission and/or at serial intervals
- Intervention (I): Nil
- (C): Nil

- Outcome (O):
 - Primary: Mortality and GOS
 - Secondary outcomes included length of hospital stay, ventilatory days, and long-term functional outcomes
 - The GOS was dichotomized according to the standard classification into favorable outcome (GOS I-III) and unfavorable outcome (GOS IV-V). GOS is a 5-point scale described by Jennett and Bond in 1975.^[4]

Eligible study designs included a prospective, cohort, retrospective, and observational study and a case series. We applied no restrictions on the minimum follow-up duration reported and study settings. There was no restriction based on the year of publication and language to minimize the risk of publication bias. Only published studies were eligible for inclusion and we sought only published data. Unpublished studies, review articles, animal studies, letters to editors, and conference abstracts were not included in the study. The study screening and selection were made as per Cochrane Collaboration Methodology.^[14] The studies where NLR was not reported were excluded from the study. The studies where the outcome of interest was not studied or not reported were excluded from the study. Studies based on TBI type and severity were included in the study. Studies reporting patients with extracranial injuries of abbreviated injury score >3 severity were excluded from the review. The second publication from the same study was also excluded from the study. There was no restriction on the age group to include a study in the systematic review.

Information sources

Relevant articles were identified by searching the electronic databases PubMed, Cochrane Library, Web of Science, and Scopus. RM and AJ performed the search, and the differences were resolved by discussion with a third reviewer (AA). In addition to the electronic search, the studies cited in the included studies, institutional repositories, relevant neurosurgery journals, and manual search using the Google Scholar website related to the subject searched. The searches were first conducted on September 11, 2021, and updated on October 20, 2021. Only human studies were selected from the electronic database wherever such a filter was available. All results were screened in other databases where such a filter option was not available. There was no restriction applied to the language of publication or publication date. We screened the reference list of the relevant articles and systematic reviews on similar topics to recognize additional eligible articles. After removing the duplicates, full-length articles were retrieved and assessed for qualitative and quantitative synthesis eligibility.

Search strategy

Line-by-line search strategy for all the databases is presented in Supplementary File S1. The search strings were validated as shown in the PUBMED search strategy. As the search was more sensitive but less specific with the use of MeSH and keywords for NLR and TBI, keywords for the search of outcome measures were not used in the search strategy. The search strategy for PUBMED is as follows: (("Neutrophils" [MeSH Terms] OR "Leukocytes" [MeSH Terms] "Lymphocytes" [MeSH Terms] OR OR "Leukocytosis" [MeSH Terms] OR "Lymphocytosis" [MeSH Terms] OR "neutrophil*" [Text Word] OR "leukocyte*" [Text Word] OR "TLC" [Text Word] OR "total leukocyte count*"[Text Word] OR "lymphocyte*"[Text Word] OR "lymphocyte count*" [Text Word] OR (("neutrophil leukocyte*"[Text Word] OR "neutrophil lymphocyte*"[Text Word]) AND ("ratio" [All Fields] OR "ratios" [All Fields] OR "ratios" [All Fields] OR "ratios" [All Fields]))) AND ("brain injuries, traumatic" [MeSH Terms] OR "Brain Concussion" [MeSH Terms] OR "TBI*" [Text Word] OR "head injury*"[Text Word] OR "brain injury*"[Text Word] OR "contusion*" [Text Word] OR "cerebral injury*" [Text Word] OR "cortical injury*" [Text Word] OR "Hematoma" [Text Word])) AND (humans[Filter]).

Selection process

Two reviewers (RM and AA) independently screened the title and abstract of each record for eligibility. The discrepancy was first resolved with mutual discussion and then with the consensus of the third reviewer (AJ).

Data extraction and effect estimates

Two reviewers (RM and AJ) performed independent data extraction using the piloted data abstraction form guided by Cochrane recommendations.^[14] In the event of a discrepancy, the third reviewer (AA) resolved the conflict unanimously. The data collected from the studies included study details, study design, sample size, country and journal of publication, study objectives, statistical measures, inclusion and exclusion criteria, outcome measures, follow-up, subgroups analyzed, results, and critical conclusions. The effect estimates reported in the studies as mean and standard deviation were used for quantitative synthesis. In studies where the median was reported with a large sample size, we calculated the mean and standard deviation according to McGrath et al. and Cochrane handbook.^[15,16] Area under the curve (AUC) reported in the studies was used to compute AUC metaanalyses of effect estimates. GOS outcome was considered most important for interpreting the review's conclusions as it was most objectively reported and not affected by other coexisting conditions. Details were collected on the setting of the study and participant characteristics, whether adult or pediatric, isolated TBI or polytrauma, and severity of TBI. GOS outcome was dichotomized as favorable (GOS I-III) and unfavorable (GOS IV-V). Effect estimates for NLR were reported as the mean difference with 95% CI.

Study quality and risk of bias assessment

Two authors (RM and AA) evaluated the study quality using the Newcastle-Ottawa scale (NOS)^[17] and the risk of bias using the RoBANS^[18] risk of bias tool for non-randomized studies. Any conflicts in the assessment were mostly resolved with mutual consensus and in some cases with the involvement of the third author (AA). Newcastle-Ottawa quality assessment scale^[17] is used to evaluate the study quality based on three domains of selection, comparability, and outcomes and consists of a set of eight questions. The question to assess comparability can have 2 points while the rest of the questionnaire items can have a maximum of 1 point each. The maximum score for a study in NOS is nine. For the present review, we considered a study with a score \geq 6 as good quality and consistent. RoBANS^[18] risk of bias tool is a 6-item tool to evaluate the risk of bias in selection, confounding, attrition, performance, and reporting bias domains in a non-randomized study.

Synthesis methods

Quantitative synthesis was done from the study's published data and effect estimates were reported for the outcome measures specified wherever available. Studies in which data were not reported or could not be computed from the reported data in a dichotomized manner were included in the systematic review but were not suitable for the quantitative synthesis. In studies where an extended Glasgow Outcome Score was reported as the outcome measure, GOS was computed. Studies that have reported outcome tools other than GOS and Extended GOS were included in the systematic review but excluded from the quantitative synthesis. The systematic review is presented as a narrative synthesis. We used the random-effects model to compute the effect estimates for the GOS and mortality. NLR was the continuous variable and the inverse variance statistical method was used. I² statistics described the heterogeneity in the studies, where low heterogeneity meant an $I^2 < 40\%$. P < 0.05 was considered statistically significant. Funnel plots were studied to identify the publication bias and variability in the studies. We did sensitivity analysis as a subgroup analysis to explore the reasons for heterogeneity.

Ethics and data

This study did not involve any human participants and did not require ethical approval. The systematic

review was prospectively registered with PROSPERO Id CRD42022285439.

RESULTS

Study selection

Seven thousand two hundred and thirteen citations were obtained from the electronic database using the search strategy. Two thousand one hundred and thirty-six records were screened after removing duplicates. After screening the title and abstract, 2097 citations were excluded from the study. The full text of 40 articles was retrieved and assessed for eligibility, of which 28 were excluded from the study. The list of excluded studies with the reason is presented in [Table 1]. Twelve articles were eligible for inclusion in the systematic review.^[8-11,19-26] Eight articles were eligible for quantitative synthesis.^[8-11,19,20,22,24] The reason for articles excluded from meta-analysis is presented in [Table 2]. The study screening and selection process are shown as flow diagram in [Figure 1].

Study characteristics

All included studies were published in English. Four studies were published from China and one each from India, Australia, the United States of America, the

Table 1: Studies excluded from the systemat	tic review.
Study Id/Year/Country	Reason for exclusion
Keskil <i>et al.</i> /1994/Turkey ^[39]	Study explored leukocytosis in TBI and did not report separately the neutrophils, lymphocytes, or NLR.
Holmin <i>et al.</i> /1998/Sweden ^[40]	Study explored the inflammation in contused brain tissue and did not match the eligibility criteria for the present SR
Rovlias and Kotsou/2001/Greece ^[41]	Assessed WBC count in severe head injury but did not report neutrophils and lymphocytes as outcome in TBI
Pagowska-Klimek <i>et al.</i> /2007/Poland ^[42]	Assessed post-injury effects on neutrophils and lymphocytes and not the outcome. Did not match the eligibility criteria of present SR
Gürkanlar <i>et al.</i> /2009/Turkey ^[33]	Assessed WBC count in severe head injury but did not report neutrophils and lymphocytes as outcome in TBI
Fitrolaki <i>et al.</i> /2013/Greece ^[43]	Assessed CD 64 expression of neutrophils and sepsis in TBI. Did not match the eligibility criteria of present SR.
Liao <i>et al.</i> /2013/China ^[44]	Assessed oxidative burst of neutrophils and did not report the NLR and outcome.
Wang et al./2014/Taiwan ^[45]	Assessed neutrophils apoptosis as predictive outcome and not NLR.
Gusdon <i>et al.</i> /2017/USA ^[46]	Assessed role of leukocytes in perihematomal growth
Liu <i>et al.</i> /2018/China ^[47]	Review article
Lattanzi <i>et al.</i> /2019/Italy ^[48]	Systematic review on stroke and neutrophils
Needham <i>et al.</i> /2019/United Kingdom ^[49]	Review article
Von Leden <i>et al.</i> /2019/USA ^[50]	Review article
Wang et al./2019/China ^[51]	Assessed NLR as predictor of hematoma growth and not the outcomes required for the present SR
Yu et al./2019/China ^[52]	Systematic review on leukocytosis in intracerebral hemorrhage and did not assess TBI
Alexiou <i>et al.</i> /2020/Greece ^[53]	Assessed NLR to predict the CT scan in TBI and did not match eligibility criteria of present SR
Bai <i>et al.</i> /2020/China ^[54]	Assessed NLR in stroke and not in TBI
Chen <i>et al.</i> /2020/China ^[55]	Assessed post-operative NLR after hematoma evacuation. The study was not on TBI and admission NLR was not assessed to predict the outcome.
Kaur et al./2020/India ^[56]	Systematic review on phytotherapeutic intervention in neuroinflammation
Korobey <i>et al.</i> /2020/USA ^[12]	Symposium paper
Kusuma <i>et al.</i> /2020/Indonesia ^[57]	The study evaluated NLR with CRP and ESR in TBI. There were no outcomes assessed.
Li <i>et al.</i> /2020/China ^[58]	Assessed NLR and DWI and did not match eligibility criteria of present SR
Sabouri <i>et al.</i> /2020/Iran ^[59]	Review article
Sadaka <i>et al.</i> /2020/USA ^[60]	Symposium paper and duplicate
Zhang <i>et al.</i> /2020/China ^[61]	Participants had chronic subdural hematoma
Gul <i>et al.</i> /2021/Turkey ^[62]	Did not assess NLR
Menon <i>et al.</i> /2021/India ^[63]	Assessed NLR in ICH and not in TBI
Radu <i>et al.</i> /2021/Romania ^[64]	Assessed NLR in ICH and not in TBI
	naboute action ICH. Intercomband homenwhere DWIL Diffusion susisked imaging CT. Commuted

TBI: Traumatic brain injury, NLR: Neutrophil-lymphocyte ratio, ICH: Intracerebral hemorrhage, DWI: Diffusion-weighted imaging, CT: Computed tomography, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate

Table 2: Studies included in the systematic review but excluded from the quantitative synthesis.

Study Id	Reason for exclusion
Dolmans <i>et al.</i> , 2020 ^[21] Kimball <i>et al.</i> , 2020 ^[26]	Data not presented in each arm of the groups compared Data on NLR were not reported for survivors versus non-survivors. Data on outcome dichotomized as favorable and non-favorable
Mukherjee <i>et al.</i> , 2020 ^[23]	were not present. The study did not reported data among survivors versus non-survivors and outcome measure used was PCPCS and not GOSE-pediatric score.
Le Bail <i>et al.</i> , 2021 ^[25]	Data on NLR and functional outcome were not reported
NLR: Neutrophil-ly	mphocyte ratio, GOSE: Extended Glasgow outcome

scale, PCPCS: Pediatric cerebral performance category scale score

United Kingdom, the Netherlands, Poland, Korea, and France.^[8-11,19-26] Only one study was a prospective and cohort study; the rest were retrospective studies.^[11] All the studies had community-dwelling participants. Two studies reported pediatric TBI patients.^[23,26] Rest studies had adult participants.^[8-11,19-22,24,25] Participants in 10 studies had isolated TBI.^[8-11,19,21,23-26] In contrast, two studies reported on patients with TBI and extracranial injuries.^[20,22] Except for two studies, all studies reported severe TBI patients (GCS ≤8).^[20,25] All studies reported day 1 NLR measured at admission, and three studies also mentioned serial measurements of NLR.[8,9,26] Mean follow-up in the included studies was 7.5 months (range: 5 days-18 months). The total number of patients evaluated in the qualitative review was 3975. The study characteristics are presented in tabular form in [Table 3]. Critical analysis of the included studies and results of individual studies with effect estimates is presented in [Table 4]. [Table 5] shows the critical variables in the included studies and literature matrix depicting the gap in knowledge in the existing literature.

Quality assessment and risk of bias

All studies were of good quality as per the NOS with a score ≥ 6 . The NOS quality assessment is shown in [Table 6]. The median NOS score of the studies was 8 with nine studies^[8-11,19,20,22-24] scoring 8/9 and three studies^[21,25,26] scoring 6/9 with a median score of 8. RoBANS risk of bias assessment is shown in [Figure 2]. There was a higher risk of detection bias in all the studies as there was no blinding reported in the outcome assessment and a low risk of reporting and performance bias. One study^[22] had an unclear risk of selection bias while the rest of the studies had a low risk of selection bias. All studies had low risk of confounding bias.




Figure 1: PRISMA flow diagram showing study search, screening, and selection process.

Results of syntheses

Seven studies were eligible for result synthesis for the predictive role of NLR in predicting GOS at a minimum follow-up of 6 months after TBI.[8-11,19,22,24] All these studies had isolated severe TBI patients and reported day 1 NLR. Four of these studies reported an association between higher admission NLR with an increased risk of unfavorable outcome.^[9,19,22,24] Three studies found that the effect estimate overlapped the null line with no significant association between the admission NLR and GOS outcome.[8,10,11] Three studies had follow ups for ≥ 12 months. A minimum followup of 6 months was reported in four studies. The total number of participants in the quantitative synthesis was 2940. A meta-analysis showed that the mean difference was -5.18 (95% confidence interval: -10.04, -0.32). The results were statistically significant, with an overall effect of Z = 2.09and P = 0.04. However, there was a high heterogeneity (I²) of 98%. This heterogeneity could be due to the difference in the study participants and the follow-up duration. Accordingly, we did a sensitivity analysis to address the heterogeneity. Even with the sensitivity analysis, the heterogeneity was

Study Id Country Study type	Country	Study type	Aim of study	Sample size	Study duration	Population description	Inclusion criteria	Exclusion criteria	Defined management and NLR	Time of NLR measurement	Tools for outcome	Outcomes measured	Subgroups reported	Follow-up duration
						and setting			measurement		measurement			
Chen et al., 2018 ^[24]	China	Retrospective observational study	To assess the value of NLR to predict outcomes in TBI	<i>n</i> =688	January 2007– April 2012	Adult with isolated TBI patients attending single institution	 I. Isolated TBI; GCS≤8; 3. Time from injury to admission≤6 h 	 Age<18 years; 2. Time from injury to admission>6 h; 3. Prior head trauma; 4. Neurological disease including stroke; 5. Antiplatelets, anticoagulants, steroids, immunosuppressant; 6. Systemic disease 	Blinded assessment of CT images and lab data; authors mentioned protocol of management and CT classification using Traumatic Coma Data Bank criteria	At admission; neutrophil count divided by lymphocyte count	Medical charts and telephonic interviews	Functional outcome as GOS (Favorable-GOS I-III; Unfavorable-GOS IV-V); mortality	Age, temperature, GCS, neurological deterioration, seizure, mechanical ventilation, TBI severity and NLR on GOS, and survival at 1 year post-trauma	l year
Chen <i>et al.</i> , 2019 ^[9]	China	Retrospective observational study	To understand relationship between peak NLR and clinical outcome in severe TBI patients	1 <i>n</i> =316	January 2013– January 2017	Adult with isolated TBI patients attending single institution	 I. Isolated TBI; GCS≤8; 3. Time from injury to admission≤24 h; 4. Two NLR measurements done at≥3 days 	 Application curves as a construction of the series of the s	Management was guided by Brain Trauma Foundation guidelines 2007	At admission and again within 12 days; neutrophil count divided by lymphocyte count; peak NLR defined as maximum NLR	Not mentioned	Functional outcome as GOS (Favorable-GOS I-III; Unfavorable-GOS IV-V)	Age, GCS, blood glucose, surgery in the first 24 h, length of hospital stay, day 1, and peak NLR with GOS at 1 year post-trauma	l year
Corbett <i>et al.</i> , 2019 ^[10]	Australia	Retrospective observational study	To compare the prognostic ability of hematologic parameters with the IMPACT prognostic	n=388	2004–2016	Adults with severe TBI requiring decompressive craniectomy	Adults with severe TBI requiring decompressive craniectomy	Not reported	Not reported	At admission	Medical database of two hospitals	Functional outcome as GOS (Favorable-GOS I-III; Unfavorable-GOS IV-V)	Hemoglobin, INR, DIC, aPTT, fibrinogen, and total leukocyte count	18 months
Siwicka-Gieroba et al., 2019 ¹⁸¹	Poland	Retrospective observational study	To analyze the effect of NLR on outcomes of severe TBI	<i>m</i> =144	Not reported	Adult with isolated TBI patients attending single institution	Consecutive adult patients with isolated severe TBI admitted to intensive care unit.	 Age<18 years; 2. Pregnant women; 3. Patients with drug overdoses; 4. Patients with history of neoplastic, cardiac, hepatic, or renal disease. 	Management was guided by Brain Trauma Foundation guidelines 2007 and ICU management defined with ICP measurement and surgery details	At admission and serially for 6 days in the ICU	Medical charts and telephonic interviews	Extended Glasgow Outcome Score at 7, 28 days, and 6 months	Correlation of outcome and variables with different TBI types and correlation of GOSE with serially measured NLR for the first 6 days	6 months

Journal of Neurosciences in Rural Practice • Volume 13 • Issue 4 • October-December 2022 | 623

	duration	Age, GCS, coagulopathy, 6 months TBI type, and mechanism of injury	rameters of 3 months riables, ISS	Age, GCS, WBC, aPPT, INR, 1 year anesthesia time, surgery time, and reoperation within 24 h	86 days	DLC, medical 6 months nanagement,
Subgroups reported		S	o _ o		c PTA, LOC	ital GCS, WBC, DLC, medical ths and surgical management, oral and CT brain
Outcomes	measured t	ts Functional ic outcome as GOS (Favorable-GOS I-III; Unfavorable-GOS IV-V)	Functional wo outcome as GOS (Favorable-GOS I-III; Unfavorable-GOS IV-V); mortality at 30 days; length of hospital stay 30 days or less.	Mortality at 1 year	GOSE pediatric score	Length of hospital stay and 6 months Pediatric Cerebral Performance Category Scale score
	outcome measurement	Medical charts and telephonic interviews	Medical database of two hospitals	Medical database	i h, Medical database	Medical database
	measurement	At admission y	At admission	At admission	<12 h, 24 h, 48 h, and 72 h	At admission within 2 h of injury
Defined management	and NLR measurement	Management was guided by Brain Trauma Foundation guidelines 2007 and management guidelines of severe traumatic brain injury 2017, neurosurgery.	Not reported	Not reported	Management as per guidelines	Not reported
Exclusion criteria		 Injury to other body parts with abbreviated injury score≥3; 2. Penetrating brain injury 	<18 years	 Reoperation; 2. Age<18 years; 3. Burr hole instead of craniotomy; 4. No surgery within 24 h of injury; 5. Conservative management. 	 Severe clinically diagnosed comorbidities; 2. Prior neurological disease; 3. Anticoagulants, steroids, or immunosuppressants; 4. Systemic disease 	Age>16 years, delayed investigation, patients without isolated TBI
Inclusion	criteria	 Confirmed TBI on CT scan; 2. Age≥14 years; Admission within 6 h after injury 	Severe TBI patients with GCS≤8	 Age>18 years; Admission within 6 h of injury; 3. Surgery within 24 h of injury 	 Age 0–18 years; 2. Isolated TBI; 3. Blood investigation within 84 h after injury 	1. Age 0–16 years; 2. Blood investigation within 2 h of injury
Population	description and setting	Adult with TBI patients attending single institution	Adult with severe TBI admitted in two academic institutes	Adult TBI patients undergoing surgery for EDH and SDH in a single center	Pediatric TBI patients attending single institution	Pediatric isolated TBI patients attending single institution
	duration	December 2004– December 2017	2005-2015	September 2010– December 2018	January 2007– December 2017	June 2006–June 2018
Sample	size	<i>n</i> =1291	n=255	<i>n</i> =200	<i>n</i> =188	<i>n</i> =201
Aim of study		To evaluate the prognostic value of NLR in predicting 6 months outcome after TBI.	To estimate routine blood parameters in severe TBI and its correlation with the outcome	To assess the value of NLR to predict 1 year mortality after surgery for EDH and SDH	To assess the value of NLR to predict outcome after TBI in pediatric patients	To assess the prognostic value of initial leukocytosis in predicting outcomes affer isolated TBI in pediatric
Study type		Retrospective observational study	ls Retrospective observational study	Retrospective observational study	Retrospective observational study	Retrospective observational study
Country		China	Netherlands	Korea	USA	United Kingdom
Study Id		Zhao <i>et al.</i> , 2019 ^[22]	Dolmans et al., 2020 ^[21]	Kim et al., 2020 ^[20]	Kimball et al., 2020 ^[26]	Mukherjee et al., 2020 ^[23]

teria Defined management and NLR and NLR ncanial Management was infection; guided by Brain f stroke, Trauma Foundation e disease; guidelines 2007 ugs and s; 5. Systemic 5. Systemic Not reported Mechanical 3.	Exclusion criteria 1. Severe extracranial injuries; 2. Infection; 3. History of stroke, autoimmune disease; 4. Use of drugs and medications; 5. Syster diseases 1. Admission>24 h after trauma; 2. Mechanics ventilation; 3. Discharge<48 h after trauma; 2. Mechanics ventilation; 4. Chroni blood disease affectin NLR	n Inclusion in criteria g 1. Age 18–60 years; 2. GCS≤12; 3. Isolated TBI 1. Adult; 2. GCS≥10 in in in	PopulationInclusionndescriptioncriteriaand settingcriteriaand settingcriteriaAdult with1. Age 18–60isolated TBIyears; 2.singleIsolated TBIsingleIsolated TBIinstitutionIsolated TBI20Adult TBIinstitution1. Adult; 2.patientsGCS>10with braincontusion insingle centersingle center	Population Inclusion on description criteria and setting criteria and setting criteria Adult with 1. Age 18–60 isolated TBI years; 2. attending Isolated TBI single institution institution Isolated TBI single institution vith brain GCS≥12; 3. contusion in isolated TBI single institution vith brain GCS≥10 vith brain GCS≥10 vith brain GCS≥10 vith brain GCS≥10
n; se; temic ter ter	 Severe- injuries Histo autoimi 4. Use c H. Use c H. Use c I. Admiss disease- disease- disease- trauma NLR 	 1. Age 18–60 3I years; 2. GCS≤12; 3. Isolated TBI 1. Adult; 2. GCS≥10 in 	Adult with1. Age 18-60isolated TBIyears; 2.nberpatientsGCS≤12; 3.attendingIsolated TBIsingleIsolated TBIinstitution1. Adult; 2.2020Adult TBI1. Adult; 2.patientsGCS≥10with braincontusion insingle centersingle center	n=96JuneAdult with1. Age 18-602019-isolated TBIyears; 2.NovemberpatientsGCS≤12; 3.2019attendingIsolated TBI2019attendingIsolated TBIinstitutioninstitutionIsolated TBI $n=115$ $2017-2020$ Adult TBI1. Adult; 2. $n=93$ JanuaryAdult DAIDAI patients
_	 Admissio trauma; 2 ventilatio Discharg admissio blood dis NLR 	1. Adult; 2. GCS≥10 in ier	Adult TBI 1. Adult; 2. patients GCS≥10 with brain contusion in single center	<i>n</i> =115 2017–2020 Adult TBI 1. Adult; 2. patients GCS≥10 with brain contusion in single center <i>n</i> =93 January Adult DAI DAI patients
Discharge<48 h after admission; 4. Chronic blood disease affecting NLR				<i>n</i> =93 January Adult DAI DAI patients
 Admission after 24 h of injury; Not reported Expired or referred to other hospital; 3. CT/MRI showing EDH/SDH; 4. Conconitant multiple organ injury/surgery; 5. Steroids/ immunosuppressants; 6. Blood collected 24 h after admission; 7. Infectious disease within 1 week of admission 	 Admission after 24 h of: Expired or referred to other hospital; 3. CT/MI showing EDH/SDH; 4. Conconitant multiple o injury/surgery; 5. Steroid immunosuppressants; 6 Blood collected 24 h afte admission; 7. Infectious disease wit 1 week of admission 	DAI patients	Adult DAI DAI patients patients attending single institution	2014– patients January attending 2020 single institution

Table 4: Pros and	cons of the included studies.		
Study Id	Results	Key Conclusions	Remarks
Chen <i>et al.</i> , 2018 ^[24]	NLR was found as significant predictor for unfavorable outcome (OR=1.100, 95% CI=1.064–1.138) and mortality (OR=1.158, 95% CI=1.094–1.226); mean NLR in favorable versus unfavorable outcome was (11.60±4.05 vs. 15.07±6.63) and mortality was 13.75±6.27 versus 18.75±7.76; predictive performance was similar to GCS in severe TBI for functional outcome and worse than GCS for mortality	Increased NLR at admission in severe TBI patients is associated with poor functional outcome and mortality at 1 year	Only adult patients with GCS≤8 within 6 h of admission were included in the study. Correlation of day 1 NLR at admission was done with functional outcome and mortality but not with the length of hospital stay, ventilator days, and GCS
Chen <i>et al.</i> , 2019 ^[9]	Age, GCS, surgery in the first 24 h, length of hospital stay, and peak NLR were significantly associated with unfavorable outcome with OR 1.086 (95% CI 1.037–1.137); peak NLR cutoff value of 18.16 with sensitivity of 74.3% and specificity of 72.9%. NLR peaked between day 2 and day 4	Day 1 NLR was associated with unfavorable outcome; however, peak NLR was significantly associated with unfavorable outcome after multivariate analysis. Day 1 NLR and GCS were associated with peak NLR in patients with severe TBI	Only adult patients with GCS≤8 within 24 h of admission were included in the study. Correlation of day 1 NLR at admission was done with functional outcome but not with the length of hospital stay, ventilator days, GCS, and mortality. The study showed that day 1 NLR was associated with peak NLR>21 and unfavorable outcome but peak NLR is better prognostic indicator than day 1 NLR.
Corbett <i>et al.</i> , 2019 ^[10]	NLR (AUROC 0.500, 95% CI 0.442– 0.559; <i>P</i> =0.998) was not a significant predictor of unfavorable outcome at 18 months in univariate or multivariate analysis	INR in isolation had the best prognostic significance in functional outcome of severe TBI patients requiring decompressive craniectomy. However, none of the hematological parameters including INR and NLR was a significant predictor of unfavorable outcome at 18 months or added additional prognostic value to IMPACT prognostic model	The study included adult patients with severe TBI requiring decompressive craniectomy and focused on abnormal hematological parameters in predicting unfavorable outcome at 18 months. Single NLR value was assessed. There was no distinction based on time of admission and correlation with admission GCS. Outcome assessed was GOS at 18 months and mortality was not reported separately.
Siwicka-Gieroba <i>et al.</i> , 2019 ^[8]	Median NLR at admission was 11.74, highest was in patients with diffuse axonal injury. NLR was significantly higher in GOSE 1, 2, and 3, and cutoff value of 15.63 was associated with significant increase in 28 days mortality risk	NLR is a significant marker of outcome after severe TBI. Higher values of admission NLR and NLR in the 1 st week were associated with severe disability in TBI patients	The admission and 1 st week NLR were correlated with the GOSE outcome at 6 months and according to the TBI type. No association with surgery, length of hospital stay, ventilator status, and mortality were reported.
Zhao <i>et al.</i> , 2019 ^[22]	NLR was significant predictor of 6-month functional outcome with OR 0.91 (95% CI; 0.89–0.93). Other significant predictors were age, admission GCS, coagulopathy, SDH, IPH, and tSAH	High day 1 NLR was a significant predictor of poor functional outcome at 6 months following TBI	Correlation of day 1 NLR at admission was done with functional outcome but not with the mortality, TBI types, length of hospital stay, ventilator days, and GCS. This study was not on isolated TBI and mean GCS was 11.21±3.70.

(Contd...)

Study Id	Results	Key Conclusions	Remarks
Dolmans <i>et al.</i> , 2020 ^[21]	No laboratory parameter was associated with length of hospital stay more than 30 days, mortality, and functional outcome at 3 months	Routine blood investigations do not predict the length of hospital stay, 30-day mortality, and 3 months functional outcome in severe TBI patients	The study described initial laboratory values in patients with severe TBI and reported the correlation with outcomes measures as OR; however, data not presented in each arm of the groups compared.
Kim et al., 2020 ^[20]	Age, GCS, Cr level, aPTT, intraoperative epinephrine, and lymphocyte count (HR=1.085, 95% CI=1.006–1.169) were significant predictors of 1-year mortality. NLR was lower among the survivors and was not a significant predictor of mortality.	Prolonged aPPT, low GCS, and increased admission lymphocyte counts were associated with higher mortality at 1 year after emergency craniectomy for EDH and SDH	The study assessed mortality at 1 year in post-surgery patients. Only EDH and SDH were included in the study. There was no separate classification as per severity of injury. Other outcome measures including functional outcome wer not reported.
Kimball <i>et al.</i> , 2020 ^[26]	NLR was higher in patients with LOC, no significant relation with PTA and GCS. NLR at 24 h and 8 h was significantly different for different GOSE, but admission NLR and 72 h NLR were not significantly different. A 24 h and 48 h NLR were higher in patients who did not survived	Higher NLR at day 1 and day 2 was associated with worse outcomes in pediatric TBI	Data on NLR were not reported for survivors versus non-survivors Data on outcome dichotomized as favorable and non-favorable were not present.
Mukherjee <i>et al.</i> , 2020 ^[23]	NLR was independent predictor of outcome in pediatric TBI (OR2.61, 95% CI 1.30–7.99). NLR cutoff of 5.2 was a significant predictor for unfavorable outcome.	NLR is an independent risk factor for poor outcome in pediatric TBI patients	The study did not reported data among survivors versus non-survivors and outcome measure used was PCPCS and not GOSE-pediatric score.
Bilgi <i>t al.</i> , 2021 ^[11]	TLC more than 20.95×10 ⁶ /L predicted mortality with 80% specificity and 50% sensitivity. Admission NLR was not a significant predictor of mortality or 6 months functional outcome	INR, TLC, and blood transfusion were significant predictor of mortality and 6 months functional outcome, whereas NLR was not a significant predictor	Data no reported separately for survivors versus non-survivors
Le Bail <i>et al.</i> , 2021 ^[25]	Higher NLR at admission was associated with neurological deterioration (18 [12–29] vs. 8 [5–13]. NLR≥15), the sensitivity and specificity were 69% and 79%	NLR at admission was an independent predictor of neurological deterioration in mild or moderate TBI	Data on NLR and functional outcome were not reported.
Xie et al., 2021 ^[19]	NLR was an independent risk factor for 6-month unfavorable outcome in diffuse axonal injury with (OR: 1.63; 95% CI: 1.222e2.129). NLR above 14.99 had sensitivity and specificity of 80.6% and 94.7% in differentiating favorable from unfavorable outcome	NLR is an independent risk factor for poor outcome and NLR with GCS is a better indicator than the NLR or GCS alone	Data on mortality not presented separately

Outcome Scale, TLC: Total leukocyte count

high. The results were not significant for the studies with 6-month follow-ups. However, the results were significant for the studies with follow-ups of more than 6 months with an effect estimate of mean difference of -2.89 (95% confidence interval: -5.96, 0.17) and P = 0.06. The forest plot is shown in [Figure 3].

Two studies qualified for result syntheses for mortality as only two reported the data of survivors versus nonsurvivors.^[20,24] The results showed that a higher admission NLR was associated with an increased mortality risk; however, the results were not significant. The number of participants for this group was 888. The effect estimate

Study ID	Adult	Adult Pediatric Isolated TBI	Isolated TBI	Severe TBI	Moderate TBI	Mild TBI	Day 1 NLR	Serial NLR	Mortality	GOS	GOS-E	Serial Mortality GOS GOS-E Pediatric GOSE NLR	Other outcome scale	Follow up
Chen <i>et al.</i> 2018 ^[24]	>		>	>			>		>	>				1 year
Chen <i>et al.</i> 2019 ^[9]	>		>	>			>	>		>				l year
Corbett <i>et al.</i> 2019 ^[10]	>		>	>			>			>				18 months
Siwicka <i>et al.</i> 2019 ^[8]	>		>	>			>	>			>			6 months
Zhao <i>et al.</i> 2019 ^[22]	>			>	>	>	>			>				6 months
Dolmans <i>et al.</i> 2020 ^[21]	>		>	>			>		>	>			Length of hospital days more than 30 davs	3 months
Kim <i>et al.</i> 2020 ^[20]	>				>	>	>		>					1 year
Kimball <i>et al.</i> 2020 ^[26]		>	>	>	>	>	>	>	>			>		86 days
Mukherjee <i>et al.</i> 2020 ^[23]		>	>	>	>	>		>				Length of hospital stay and pediatric cerebral performance category scale score (PCPCS)	6 months	
Bilgi <i>et al.</i> 2021 ^[11]	>		>	>	>	>	>		>		>		14 day mortality	6 months
Le Bail <i>et al.</i> 2021 ^[25]	>		>		>	>	>						Neurological deterioration, length of hospital stay	5 days
Xie <i>et al.</i> 2021 ^[19]	>		>	>	>		>			>				6 months

Table 6: Quality of	Table 6: Quality of studies according to the Newcastle-Ottawa scale.	he Newcastle-Ot	tawa scale.						
Groups	Selection				Comparability	Outcome			Total
Study Id	Representativeness of sample	Selection of the non-exposed cohort	Ascertainment of prognostic variable	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow-up of cohorts	score
Chen <i>et al.</i> , 2018 ^[24]	*	*	*	*	*	*	*	*	8/9
Chen <i>et al.</i> , 2019 ^[9]	*	*	*	*	*	*	*	*	8/9
Corbett <i>et al.</i> , 2019 ^[10]	*	*	*	*	*	*	*	*	8/9
Siwicka-Gieroba et al., 2019 ^[8]	*	*	*	*	*	*	*	*	8/9
Zhao <i>et al.</i> , 2019 ^[22]	*	*	*	*	*	*	*		8/9
Dolmans <i>et al.</i> , 2020 ^[21]	*	*	*	*	*	*			6/9
Kim <i>et al.</i> , 2020 ^[20]	*	*	*	*	*	*	*	*	8/9
Kimball <i>et al.</i> , 2020 ^[26]	*	*	*	*	*	*			6/9
Mukherjee <i>et al.</i> , 2020 ^[23]	*	*	*	*	*	*	*	*	8/9
Bilgi <i>et al.</i> , 2021 ^[11]	*	*	*	*	*	*	*	*	8/9
Le Bail <i>et al.</i> , 2021 ^[25]	*	*	*	*	*	*			6/9
Xie <i>et al.</i> , 2021 ^[19]	*	*	*	*	*	*	*	*	8/9
★ Indicates that it m	\bigstar Indicates that it meets criteria in Newcastle-Ottawa Scale	-Ottawa Scale							

was a mean difference of -3.22 (95% confidence interval: -7.12, 0.68), P = 0.11, and I² 85%. The forest plot of the analysis is shown in [Figure 4]. The funnel plot for the synthesis of the results is shown in [Figure 5]. Meta-analysis for AUC receiver operating characteristic (ROC) of the included studies showed good predictive power of NLR in predicting outcomes following TBI with AUC 0.706 (95% CI: 0.582–0.829). The results for different studies with 95% CI and the pooled area under ROC in fixed-effect and randomeffect models with 95% CI are shown in [Figure 6]. [Table 7] details the statistical methods and effect estimates of result syntheses and sensitivity analysis.

DISCUSSION

The present systematic review evaluated the available evidence on the prognostic role of predicting admission NLR in predicting outcomes following TBI. Twelve studies were included for the qualitative synthesis. The outcome measures for the quantitative synthesis were GOS and mortality. A limited number of studies reported on other outcome measures of length of hospital stay and intensive care unit (ICU) stay, and therefore, the meta-analysis could not be done. NLR as a prognostic indicator of functional outcome after TBI is complex. Most published studies reported day




Figure 2: (a) Risk of bias assessment in included studies using RoBANS. A summary table of review authors' judgments for each risk of bias item for each study, (b) RoBANS risk of bias graph: Review authors' judgments about each risk of bias item presented as percentages across all included studies.

	Favoura	ble (GOS	1.3)	Unfavou	able (GOS	4.5)		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD		Weight	IV. Random, 95% CI	Year	IV. Random, 95% Cl
1.1.1 GOS at >= 6 month		00	Total	moun	00	Total	rioigin	10,1141140111,007.01	Total	ing running conv or
Chen 2018	11.6	4.05	180	15.07	6.63	508	7.5%	-3.47 [-4.30, -2.64]	2018	
Corbett 2019	8.7	9.18	237	7.97	6.93	151	7.4%	0.73 [-0.88, 2.34]		+
Siwicka-Gieroba 2019	15.5	14.46	41	14.12	6.57	27	6.3%	1.38 [-3.69, 6.45]		
Chen 2019	11.43	4.07	59	17.22	5.56	257	7.5%	-5.79 [-7.03, -4.55]		-
Zhao 2019	7.68	6.54	950	24.71	12.52	341		-17.03 [-18.4215.64]		÷
Xie 2021	10.14	5.29	57	21.01	7.17	36	7.2%	-10.87 [-13.59, -8.15]		-
Bilgi 2021	15.4	10.4	39	15.5	9.4	57	6.7%	-0.10 [-4.18, 3.98]		-
Subtotal (95% CI)			1563			1377	50.0%	-5.18 [-10.04, -0.32]		•
Heterogeneity: Tau ² = 40	.99; Chi ² =	372.33.	df = 6 (P	< 0.00001)	: I ² = 98%					
Test for overall effect: Z =	2.09 (P =	0.04)								
1.1.2 Sensitivity analysis	s for GOS	at 6 mont	hs							
Zhao 2019	7.68	6.54	950	24.71	12.52	341	7.4%	-17.03 [-18.42, -15.64]	2019	-
Siwicka-Gieroba 2019	15.5	14.46	41	14.12	6.57	27	6.3%	1.38 [-3.69, 6.45]	2019	
Bilgi 2021	15.4	10.4	39	15.5	9.4	57	6.7%	-0.10 [-4.18, 3.98]	2021	+
Xie 2021	10.14	5.29	57	21.01	7.17	36	7.2%	-10.87 [-13.59, -8.15]	2021	-
Subtotal (95% CI)			1087			461	27.6%	-6.89 [-15.35, 1.58]		-
Heterogeneity: Tau ² = 71			df = 3 (P	< 0.00001)	; l² = 97%					
Test for overall effect: Z =	: 1.59 (P =	0.11)								
1.1.3 Sesnitivity analysis	s for GOS	at > 6 mo	nths							
Chen 2018	11.6	4.05	180	15.07	6.63	508	7.5%	-3.47 [-4.30, -2.64]	2018	•
Chen 2019	11.43	4.07	59	17.22	5.56	257	7.5%	-5.79 [-7.03, -4.55]	2019	-
Corbett 2019	8.7	9.18	237	7.97	6.93	151	7.4%	0.73 [-0.88, 2.34]	2019	.†
Subtotal (95% CI)			476			916	22.4%	-2.89 [-5.96, 0.17]		•
Heterogeneity: Tau ² = 6.9			= 2 (P < 0	.00001); I ²	= 95%					
Test for overall effect: Z =	: 1.85 (P =	0.06)								
Total (95% CI)			3126			2754	100.0%	-5.21 [-8.35, -2.06]		◆
Heterogeneity: Tau ² = 34	.15; Chi ² =	744.67,	df = 13 (F	< 0.00001); I ² = 98%					-50 -25 0 25 50
Test for overall effect: Z =	3.24 (P =	0.001)								-50 -25 0 25 50 Favours (favourable GOS) Favours [UnfavourableGOS]
Test for subgroup differe	nces: Chi ^a	= 1.16, d	f= 2 (P =	0.56), I ² =	0%					Favous liavonianie 2031 Favous [Olliavonianie003]
101.0										

Figure 3: Forest plot of neutrophil-to-lymphocyte ratio and Glasgow Outcome Scale outcome.

	St	IIVİVOI		Non-	surviv	юг		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	r IV, Random, 95% Cl
Chen 2018	13.75	6.27	440	18.75	7.76	248	55.5%	-5.00 [-6.13, -3.87]	2018	3 📕
Kim 2020	5.6	6.9	98	6.6	12.8	102	44.5%	-1.00 [-3.83, 1.83]	2020	•
Total (95% CI)			538			350	100.0%	-3.22 [-7.12, 0.68]		•
Heterogeneity: Tau ² = Test for overall effect:				= 1 (P =	0.01);	l² = 85'	%			-100 -50 0 50 100 Favours [Survivor] Favours [Non-survivor]

Figure 4: Forest plot of neutrophil-to-lymphocyte ratio and mortality outcome.

Outcome or subgroup	Studies	Participants	Statistical method	Effect estimate
1.1. GOS	7	5880	Mean difference (IV, random, 95% CI)	-5.21 [-8.35, -2.06]
1.1.1. GOS at≥6 months	7	2940	Mean difference (IV, random, 95% CI)	-5.18 [-10.04, -0.32]
1.1.2. Sensitivity analysis for GOS at 6 months	4	1548	Mean difference (IV, random, 95% CI)	-6.89 [-15.35, 1.58]
1.1.3. Sensitivity analysis for GOS at>6 months	3	1392	Mean difference (IV, random, 95% CI)	-2.89 [-5.96, 0.17]
1.2. Mortality	2	888	Mean difference (IV, random, 95% CI)	-3.22 [-7.12, 0.68]

GOS: Glasgow Outcome Scale, NLR: Neutrophil-to-lymphocyte ratio




Figure 5: (a) Funnel plot for studies reporting Glasgow Outcome Scale outcome, (b) funnel plot for studies reporting mortality outcome.

Chen et al. 2018 Chen et al. 2019 Corbett et al. 2019 Zhao et al. 2019 Bilgi et al. 2021 Xie et al. 2021 Total (fixed effects) Total (random effects) 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Area under ROC curve

Figure 6: Meta-analysis of AUC ROC for neutrophil-to-lymphocyte ratio predicting Glasgow Outcome Scale outcome.

1 NLR as a predictor of outcome, while NLR is a dynamic entity. Chen *et al.*^[9] showed that day 1 NLR was significantly associated with peak NLR >21 in patients with severe TBI. NLR peaked between day 2 and day 4. However, researchers found that only peak NLR was a significant predictor in multivariate analysis. This implies that day 1 NLR, though it predicts a peak rise in NLR, is peak NLR which is a better prognostic indicator.

Significant heterogeneity was observed among the included studies in terms of the follow-up. The studies are limited to severe TBI, and only one study focused on delayed deterioration in patients with TBI with GCS >10.^[20] Most of the studies involved adult patients – two studies reported in the pediatric age group.^[23,26] Zhao *et al.*^[22] reported that the predictive value of NLR was better when used in the model along with other predictive parameters than with the NLR being used alone.

The present systematic review found that the admission NLR predicts the GOS with statistical significance. Higher NLR was associated with an increased risk of unfavorable outcomes at 6 months and more than 12 months follow-up. However, the certainty of the evidence was low due to high heterogeneity due to the changes in the study participants. The heterogeneity remained high in the sensitivity analysis, suggesting that the follow-up duration was not a factor responsible for high heterogeneity.

Studies have explored the role of neutrophils in the adverse outcomes following TBI. Neutrophils are present in circulation but not usually present in the brain parenchyma due to the blood-brain barrier.^[7] Limited neutrophils are present in cerebrospinal fluid, pia, and meninges; however, pathological invasion of neutrophils in the brain parenchyma occurs in trauma, infection, ischemia, and hemorrhage.^[27] Neutrophils result in tissue damage by phagocytosis, degranulation, and neutrophil extracellular trap. The accumulation of neutrophils is mediated by several receptors signaling the danger signal. Neutrophils can augment autocrine-dependent activation even when the danger signal has passed.^[28-30] This led to indiscriminate tissue damage and neutrophils and was stopped by macrophages and lymphocytes. A similar mechanism is thought to activate after the trauma with the invasion and activation of neutrophils in the damaged brain due to TBI. The brain is a privileged immune organ due to the blood-brain barrier. However, there is invasion and instant activation of microglia and neutrophils in the damaged brain.^[2,27,31,32] Recently discovered lymphatic channels lining the dural sinuses with characteristic lymphatic endothelial lining showed that once thought immune privilege status of the brain is changed. These channels provide a route for entry and exit of peripheral immune cells to the brain.^[1,33] The primary injury sets the stage for secondary brain injury, resulting in edema and reduced cerebral blood flow. The shear stress results from the mechanical forces due to the primary impact disrupting axons and blood vessels. This results in cerebral edema, the release of inflammatory cytokines, disruption of the blood-brain barrier, neuroinflammation, and invasion of the peripheral immune system.^[34] Animal and human studies showed that there is hypoperfusion in the early stages of TBI and results in poor neurological outcome.[35-38] This hypoperfusion results in activation and accumulation of neutrophils and the rheological action of neutrophils in blood vessels. Accordingly, increased local neutrophils result in indiscriminate brain damage. Researchers identified that this local increase in the neutrophil count at the damaged brain site is reflected in increased neutrophils in the peripheral blood. Several studies found that increased neutrophils after TBI and increased NLR predict poor functional outcome. A study by Bilgi et al.^[11] reported that NLR was not superior to the CRASH and IMPACT scoring system in predicting mortality or functional outcome. Similarly, the study by Korobey et al.^[12] reported that the predictive power of NLR was inferior to the CRASH predictive model, and no additional value was obtained when NLR was included in the predictive model system.

Clinical implications

NLR is a routine and straightforward investigation done in TBI patients. The NLR at admission is a simple biomarker for predicting the functional outcome (GOS) at 6 months. The predictive power of NLR is better when GOS is assessed at 12 months. However, the strength of the evidence available is low. The available evidence is for the adult population. TBI and inflammation are different in children as compared to adults. There is no evidence currently available to recommend NLR as a predictive biomarker of outcome following TBI in children.

Research implications

There was high heterogeneity among the available studies. The future studies focusing on the predictive value of NLR in children, predictive value according to the severity of TBI, and type of TBI will be more beneficial and informative to make clinical recommendations. Studies exploring other outcome measures, including length of hospital stay, ICU stay, ventilator days, and long-term functional outcomes, including cognitive function and long-term complications including neurocognitive sequelae and dementia, will be more meaningful. The strength of recommendations from this review is very low as the studies included were retrospective in nature, we recommend more high-end prospective research controlling the confounding factors in this topic.

Limitations

Most of the studies included in the present systematic review were retrospective studies and posed limitations in the strength of the evidence available. The heterogeneity in the participant characteristics in terms of types of TBI and severity of TBI is a significant limitation. Non-availability of comparison with standard prognostic indicators such as GCS limits the quality of available evidence. One of the limitations we faced which can influence the generalizability of these results is that the authors in the included studies did not mention the medications used in the pre-hospital treatment or intra-hospital treatment phase and this can affect the NLR in these patients. Although most of the studies mention including patients within 24 h of trauma and measuring day 1 NLR, there is variability among the studies about the time gap of collection of samples for NLR analysis from the trauma and this could affect the results.

CONCLUSION

NLR is a simple biomarker that is routinely performed in TBI patients and can significantly predict the outcome assessed by GOS at 6 months. High NLR is associated with an increased risk of unfavorable outcomes following TBI. There was no significant correlation between the NLR and mortality. The AUC ROC meta-analysis showed good predictive power of NLR in predicting GOS outcome following TBI with AUC 0.706 (95% CI: 0.582–0.829). The strength of evidence is low, making clinical recommendations of low strength to

recommend using NLR as a stand-alone predictive tool in TBI patients.

Acknowledgments

We acknowledge the support of library of our institute.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- 1. Hazeldine J, Lord JM, Belli A. Traumatic brain injury and peripheral immune suppression: Primer and prospectus. Front Neurol 2015;6:235.
- 2. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007;99:4-9.
- 3. Kim E, Lauterbach EC, Reeve A, Arciniegas DB, Coburn KL, Mendez MF, *et al.* Neuropsychiatric complications of traumatic brain injury: A critical review of the literature (a report by the ANPA Committee on Research). J Neuropsychiatry Clin Neurosci 2007;19:106-27.
- 4. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975;1:480-4.
- 5. Hazeldine J, Hampson P, Lord JM. The impact of trauma on neutrophil function. Injury 2014;45:1824-33.
- 6. Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008;209:378-88.
- Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011;11:519-31.
- 8. Siwicka-Gieroba D, Malodobry K, Biernawska J, Robba C, Bohatyrewicz R, Rola R, *et al.* The neutrophil/lymphocyte count ratio predicts mortality in severe traumatic brain injury patients. J Clin Med 2019;8:E1453.
- 9. Chen J, Qu X, Li Z, Zhang D, Hou L. Peak neutrophilto-lymphocyte ratio correlates with clinical outcomes in patients with severe traumatic brain injury. Neurocrit Care 2019;30:334-9.
- Corbett JM, Ho KM, Honeybul S. Prognostic significance of abnormal hematological parameters in severe traumatic brain injury requiring decompressive craniectomy. J Neurosurg 2019;132:545-51.
- 11. Bilgi K, Gopalakrishna KN, Chakrabarti D, Rao GS. Outcome prediction of TBI: Are there parameters that affect the IMPACT and CRASH models? World Neurosurg 2021;146:e590-6.
- 12. Korobey M, Moynihan M, Sadaka F. Neutrophil/lymphocyte

ratio and neurologic outcome in traumatic brain injury: Comparison to crash. Crit Care Med 2020;48:848.

- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, *et al.* The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- 14. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, *et al.* Cochrane Handbook for Systematic Reviews of Interventions. New York: John Wiley and Sons; 2019.
- 15. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, *et al.*, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. 2022. Available from: www.training. cochrane.org/handbook [Last accessed on 2022 Feb 05].
- McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A, DEPRESsion Screening Data (DEPRESSD) Collaboration. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res 2020;29:2520-37. Doi: 10.1177/0962280219889080.
- 17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5.
- Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, *et al.* Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013;66:408-14.
- 19. Xie QJ, Huang W, Shen L, Wang MH, Liu KF, Liu F. Combination of neutrophil-to-lymphocyte ratio and admission glasgow coma scale score is independent predictor of clinical outcome in diffuse axonal injury. World Neurosurg 2021;152:e118-27.
- 20. Kim NY, Lim J, Lee S, Kim K, Hong JH, Chun DH. Hematological factors predicting mortality in patients with traumatic epidural or subdural hematoma undergoing emergency surgical evacuation: A retrospective cohort study. Medicine (Baltimore) 2020;99:e22074.
- 21. Dolmans RG, Hulsbergen AF, Gormley WB, Broekman ML. Routine blood tests for severe traumatic brain injury: Can they predict outcomes? World Neurosurg 2020;136:e60-7.
- 22. Zhao JL, Du ZY, Yuan Q, Yu J, Sun YR, Wu X, *et al.* Prognostic value of neutrophil-to-lymphocyte ratio in predicting the 6-month outcome of patients with traumatic brain injury: A retrospective study. World Neurosurg 2019;124:e411-6.
- 23. Mukherjee S, Sivakumar G, Goodden JR, Tyagi AK, Chumas PD. Prognostic value of leukocytosis in pediatric traumatic brain injury. J Neurosurg Pediatr 2020;27:335-45.
- 24. Chen W, Yang J, Li B, Peng G, Li T, Li L, *et al.* Neutrophil to lymphocyte ratio as a novel predictor of outcome in patients with severe traumatic brain injury. J Head Trauma Rehabil 2018;33:E53-9.
- 25. Le Bail A, Jardine CG, Cottenceau V, Petit L, Matthieu Biais, Carrie C. Ability of neutrophil-to-lymphocyte ratio to predict secondary neurological impairment in patients with mild to moderate head injury. A retrospective study. Am J Emerg Med 2021;50:46-50.
- 26. Kimball R, Shachar E, Eyerly-Webb S, Patel DM, Spader H. Using the neutrophil-to-lymphocyte ratio to predict outcomes in pediatric patients with traumatic brain injury. Clin Neurol Neurosurg 2020;193:105772.
- 27. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010;120:1368-79.

- 28. Fortin CF, Ear T, McDonald PP. Autocrine role of endogenous interleukin-18 on inflammatory cytokine generation by human neutrophils. FASEB J 2009;23:194-203.
- 29. Surette ME, Krump E, Picard S, Borgeat P. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: Inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4). Mol Pharmacol 1999;56:1055-62.
- Au BT, Williams TJ, Collins PD. Zymosan-induced IL-8 release from human neutrophils involves activation via the CD11b/ CD18 receptor and endogenous platelet-activating factor as an autocrine modulator. J Immunol 1994;152:5411-9.
- Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, *et al.* Structural and functional features of central nervous system lymphatic vessels. Nature 2015;523:337-41.
- 32. Werner JK, Stevens RD. Traumatic brain injury: Recent advances in plasticity and regeneration. Curr Opin Neurol 2015;28:565-73.
- Gürkanlar D, Lakadamyali H, Ergun T, Yilmaz C, Yücel E, Altinörs N. Predictive value of leucocytosis in head trauma. Turk Neurosurg 2009;19:211-5.
- 34. Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. Exp Neurol 2013;246:35-43.
- Coles JP, Fryer TD, Smielewski P, Rice K, Clark JC, Pickard JD, et al. Defining ischemic burden after traumatic brain injury using 150 PET imaging of cerebral physiology. J Cereb Blood Flow Metab 2004;24:191-201.
- 36. Inoue Y, Shiozaki T, Tasaki O, Hayakata T, Ikegawa H, Yoshiya K, *et al.* Changes in cerebral blood flow from the acute to the chronic phase of severe head injury. J Neurotrauma 2005;22:1411-8.
- 37. Stein DM, Hu PF, Brenner M, Sheth KN, Liu KH, Xiong W, *et al.* Brief episodes of intracranial hypertension and cerebral hypoperfusion are associated with poor functional outcome after severe traumatic brain injury. J Trauma 2011;71:364-73.
- Kelly DF, Martin NA, Kordestani R, Counelis G, Hovda DA, Bergsneider M, *et al.* Cerebral blood flow as a predictor of outcome following traumatic brain injury. J Neurosurg 1997;86:633-41.
- 39. Keskil S, Baykaner MK, Ceviker N, Aykol S. Head trauma and leucocytosis. Acta Neurochir (Wien) 1994;131:211-4.
- Holmin S, Söderlund J, Biberfeld P, Mathiesen T. Intracerebral inflammation after human brain contusion. Neurosurgery 1998;42:291-8.
- 41. Rovlias A, Kotsou S. The blood leukocyte count and its prognostic significance in severe head injury. Surg Neurol 2001;55:190-6.
- 42. Pagowska-Klimek I, Lewkowicz P, Banasik M, Krajewski W, Tchórzewski H. Isolated head injury in children affects the neutrophil function and lymphocyte count. J Trauma 2007;63:179-86.
- 43. Fitrolaki DM, Dimitriou H, Kalmanti M, Briassoulis G. CD64-Neutrophil expression and stress metabolic patterns in early sepsis and severe traumatic brain injury in children. BMC Pediatr 2013;13:31.
- 44. Liao Y, Liu P, Guo F, Zhang ZY, Zhang Z. Oxidative burst of circulating neutrophils following traumatic brain injury in human. PLoS One 2013;8:e68963.

- 45. Wang HC, Yang TM, Lin YJ, Chen WF, Ho JT, Lin YT, *et al.* Serial serum leukocyte apoptosis levels as predictors of outcome in acute traumatic brain injury. Biomed Res Int 2014;2014:720870.
- 46. Gusdon AM, Gialdini G, Kone G, Baradaran H, Merkler AE, Mangat HS, *et al.* Neutrophil-lymphocyte ratio and perihematomal edema growth in intracerebral hemorrhage. Stroke 2017;48:2589-92.
- 47. Liu YW, Li S, Dai SS. Neutrophils in traumatic brain injury (TBI): Friend or foe? J Neuroinflammation 2018;15:146.
- Lattanzi S, Brigo F, Trinka E, Cagnetti C, Di Napoli M, Silvestrini M. Neutrophil-to-lymphocyte ratio in acute cerebral hemorrhage: A system review. Transl Stroke Res 2019;10:137-45.
- 49. Needham EJ, Helmy A, Zanier ER, Jones JL, Coles AJ, Menon DK. The immunological response to traumatic brain injury. J Neuroimmunol 2019;332:112-25.
- Von Leden RE, Parker KN, Bates AA Noble-Haeusslein LJ, Donovan MH. The emerging role of neutrophils as modifiers of recovery after traumatic injury to the developing brain. Exp Neurol 2019;317:144-54.
- 51. Wang Z, Gong Q, Guo C, Luo Y, Chen L. Neutrophil-tolymphocyte ratio predicts hematoma growth in intracerebral hemorrhage. J Int Med Res 2019;47:2970-5.
- 52. Yu Z, Zheng J, Guo R, Ma L, You C, Li H. Prognostic impact of leukocytosis in intracerebral hemorrhage: A PRISMAcompliant systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e16281.
- 53. Alexiou GA, Lianos GD, Tzima A, Sotiropoulos A, Nasios A, Metaxas D, *et al.* Neutrophil to lymphocyte ratio as a predictive biomarker for computed tomography scan use in mild traumatic brain injury. Biomark Med 2020;14:1085-90.
- 54. Bai X, Wang C, Wang L, Jiang S, Zhang S, Liu M, *et al.* Association between neutrophil to lymphocyte ratio and malignant brain edema in patients with large hemispheric infarction. Curr Neurovasc Res 2020;17:429-36.
- 55. Chen W, Wang X, Liu F, Tian Y, Chen J, Li G, *et al.* The predictive role of postoperative neutrophil to lymphocyte ratio for 30-day mortality after intracerebral hematoma evacuation. World Neurosurg 2020;134:e631-5.
- Kaur N, Chugh H, Sakharkar MK, Dhawan U, Chidambaram SB, Chandra R. Neuroinflammation mechanisms and phytotherapeutic intervention: A systematic review. ACS Chem Neurosci 2020;11:3707-31.
- 57. Kusuma GF, Maliawan S, Mahadewa TG, Senapathi TG. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as an inflammatory biomarker in predicting the severity of secondary brain injury: A review article. Open Access Maced J Med Sci 2020;8:272-82.
- 58. Li JW, Xu YY, Chen YJ, Fan WW, Xu XH, Cai JS, et al. Early elevated neutrophil-to-lymphocyte ratio associated with remote diffusion-weighted imaging lesions in acute intracerebral hemorrhage. CNS Neurosci Ther 2020;26:430-7.
- 59. Sabouri E, Majdi A, Jangjui P, Rahigh Aghsan S, Naseri Alavi SA. Neutrophil-to-lymphocyte ratio and traumatic brain injury: A review study. World Neurosurg 2020;140:142-7.
- 60. Sadaka F, Korobey M, Moynihan M. Predicting mortality in traumatic brain injury: Comparison of neutrophil/lymphocyte ratio and crash. Crit Care Med 2020;48:172.

- 61. Zhang Y, Yang Y, Long S, Li G. Assessment of peripheral blood cell inflammatory markers in patients with chronic subdural hematoma. Clin Neurol Neurosurg 2020;191:105738.
- 62. Gul HF, Şimşek AT, Dolanbay T, Aras M, Gul UY, Sahin L, *et al.* Evaluation of blood glucose and inflammation markers in pediatric head injuries. East J Med 2021;26:67-74.
- 63. Menon G, Johnson SE, Hegde A, Rathod S, Nayak R, Nair R. Neutrophil to lymphocyte ratio a novel prognostic marker following spontaneous intracerebral haemorrhage. Clin Neurol Neurosurg 2021;200:106339.
- 64. Radu RA, Terecoasă EO, Tiu C, Ghiță C, Nicula AI, Marinescu AN, *et al.* Neutrophil-to-lymphocyte ratio as an independent predictor of in-hospital mortality in patients with acute intracerebral hemorrhage. Medicina (Kaunas) 2021;57:622.

How to cite this article: Mishra RK, Galwankar S, Gerber J, Jain A, Yunus M, Cincu R, *et al*. Neutrophil-lymphocyte ratio as a predictor of outcome following traumatic brain injury: Systematic review and metaanalysis. J Neurosci Rural Pract 2022;13:618-35.